XRAY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
DENTSPLY SIRONA Inc (XRAY) is not a strong buy at the moment for a beginner investor with a long-term horizon and $50,000-$100,000 available for investment. The stock's technical indicators are neutral, options data suggests bearish sentiment, and the company's financial performance shows declining trends. While there are no significant positive catalysts, the stock is trading near its support level, which could attract cautious interest. However, given the lack of strong growth prospects and no recent signals from Intellectia Proprietary Trading Signals, holding off on buying is recommended.
The stock's MACD is slightly positive at 0.0265, indicating mild bullish momentum, but it is contracting. RSI is neutral at 50.545, suggesting no clear trend. Moving averages are converging, and the stock is trading near its pivot level of 12.998, with resistance at 13.913 and support at 12.083. Overall, the technical indicators are neutral.
NULL identified. No significant news or positive developments were reported recently. Analysts' ratings are mixed but slightly lean towards a buy.
Options data indicates bearish sentiment. Analysts have lowered price targets in recent months, and there is no recent congress trading activity to suggest confidence from influential figures.
In Q3 2025, revenue dropped by -4.94% YoY to $904M, net income fell by -13.56% YoY to -$427M, EPS declined by -13.01% YoY to -2.14, and gross margin decreased by -6.28% YoY to 48.78. The company is facing financial challenges with no clear signs of recovery.
Analysts' ratings are mixed. UBS maintains a Buy rating with a lowered price target of $16. Mizuho raised its price target to $14 with a Neutral rating, citing a positive dental industry outlook. Baird lowered its target to $12 with a Neutral rating, and Barclays initiated coverage with an Underweight rating and a $12 target. Overall, sentiment is cautious with no strong consensus.
